<DOC>
	<DOCNO>NCT00415649</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability immune response HIV DNA vaccine follow adenoviral vector HIV vaccine healthy African adult risk HIV infection .</brief_summary>
	<brief_title>Safety Immune Response HIV DNA Plasmid Vaccine Followed HIV Adenoviral Vector Vaccine Healthy African Adults</brief_title>
	<detailed_description>Due availability antiretroviral therapy , AIDS-related death lessen United States . However , therapy widely inaccessible develop world . The need safe affordable vaccine prevent HIV infection utmost importance . To generate broadly protective vaccine , necessary develop multivalent vaccine containing define combination immunogen globally prevalent HIV subtypes . This study evaluate safety , tolerability , immunogenicity multiclade HIV-1 DNA plasmid vaccine , VRC-HIVDNA016-00-VP , follow multiclade recombinant HIV-1 adenoviral vector vaccine , HIVADV014-00-VP . This study last 27 month . Participants randomly assign one two group . Group A receive DNA vaccine baseline , Month 1 , Month 2 , adenoviral vector vaccine Month 6 ; Group B receive placebo . There 20 study visit 2 year . Physical exam , vital sign measurement , adverse event evaluation , medical medication history occur visit . HIV test counsel blood urine collection occur select visit .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At risk HIV Have sexual intercourse HIV infect partner OR sexual intercourse one person within 3 month prior study entry OR infect sexually transmitted disease within 3 month prior study entry Willing comply protocol Willing undergo HIV test HIV counsel receive HIV test result Willing use acceptable form contraception HIV1 HIV2 infect History immunodeficiency autoimmune disease Use corticosteroid immunosuppressive , antiviral , anticancer , medication consider significant investigator within 6 month prior study entry Certain abnormal laboratory value Acute chronic medical condition consider progressive Hepatitis B hepatitis C virus infection untreated syphilis Live attenuate vaccine within 30 day prior study Planned receipt investigational product within 30 day first vaccination Other medically indicate subunit kill vaccine within 14 day prior study entry Planned receipt medically kill vaccine investigational product within 14 day first vaccination Blood transfusion within 120 day study entry Immunoglobulin within 60 day study entry Participation within last 3 month , plan participation another clinical study investigational product currently course study Another investigational HIV vaccine time History severe local systemic reactogenicity vaccine History severe allergic reaction History recurrent urticaria Major psychiatric illness , include history schizophrenia severe psychosis , bipolar disorder require therapy , suicide attempt ideation 3 year prior study entry Uncontrolled hypertension Pregnant , breastfeeding , plan become pregnant within 4 month follow last study vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>